Lodgeur provides its guests with hotel luxury with room to breathe. Courtesy of Lodgeur

In 2018, Houston set a new tourism record with 22.3 million visitors to the city. That same year, Sébastien Long was finishing his Cambridge thesis on home-sharing companies like Airbnb and falling in love with a classmate. When the couple moved to Houston after graduation, Long brought his ideas with him, and that's how Lodgeur was born.

Lodgeur works as an upscale home-sharing startup that offers luxury apartments in midtown and downtown Houston for nightly rent. It doesn't replace Airbnb; customers can browse through and book the properties through the familiar website. Guests can also book short or extended stays directly with Lodgeur's website.

In short, Long's research found that most Airbnb's have high guest experience ratings, but those user reviews don't work to inspire the 90 percent of Americans who haven't used a homestay service. Those people have worries — mostly about what to expect, about safety, and about having to interact with homeowners. Long believes he can calm those fears by building a trusted brand that customers recognize on Airbnb, and Houston turned out to be the perfect place to do that: his main inspiration, Conrad Hilton, did the same with hotels over the last century.

"Houston has been a city that's been overlooked. Most companies didn't come here first," Long says. "Actually, people are coming to Houston every week of the year, prices don't fluctuate too much, and you're probably going to be running at a high occupancy every week of the year."

So Long drove around the city, looking for apartment buildings he liked and hoped his guests would, too. Having grown up working at the campground-turned-resort started by his parents in the French Mediterranean, he had an eye for what tourists found attractive — buildings with character, high-end aesthetics and clean designs like a hotel, but with modern kitchen appliances and more space.

"We're roughly split between leisure guests and business travelers," Long says. "They want to feel like they're staying in a home away from home."

Getting that experience is about the same price as a hotel. The properties range from $90 per night to a $200 apartment with 50 feet of floor-to-ceiling windows overlooking downtown. The apartments have not just attracted outside visitors; people have come from around Houston to stay during home renovations or when their houses have flooded, Long says.

The first guests arrived in mid-April. Long wanted to open by managing just a few properties, to make sure the company could ensure great guest experiences.

Last week, he hired his first full-time employee — an ex-marine who graduated from the University of Houston's Conrad Hilton College of Hospitality — and has contracted a marketing agency to turn up Lodgeur's social media presence. For now, Lodgeur relies on a freelance interior designer to fashion the apartments and a local housekeeping company to keep them clean.

Long — who is a Station Houston and WeWork Labs member — says he is looking to expand, but he wants to do so organically: Many of the owners of properties he's already renting own other apartment complexes, and he plans to work with them to move Lodgeur out of inner Houston, and then to other cities. Lodgeur isn't raising funds yet, but Long says he'll be looking for investors this summer.

Recently, Long stayed at Hilton in Austin — his first time at a hotel since launching Lodgeur. He booked a room with a king-sized bed, but it felt small. Business requires him to carry a tape measure, so he measured the mattress: it was six inches smaller than the mattresses Lodgeur uses. He laughed, thinking of how much more comfortable guests would be in an apartment with bigger beds and more space.

"I don't know how people would go back (to hotels)," he says.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.